Navigation Links
Cepheid Signs Group Purchasing Contract with Novation, the Nation's Largest Healthcare Contracting Organization
Date:5/20/2008

proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to product performance and utility, and future market opportunities and market size. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen manufacturing problems; regulatory developments and practices regarding testing levels; customer and market acceptance of the product; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the products; the fact that VHA, UHC and Provista members have no commitment to purchase any products, and there can be no assurance that they will do so in the future; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ include
'/>"/>

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Cepheid to Present at the Robert W. Baird Growth Stock Conference and the Bank of America Healthcare Conference
2. Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results
3. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
4. Cepheid Reports Fourth Quarter and Full Year 2007 Results
5. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
6. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
9. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
10. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
11. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3
...n Trials to Begin Later This Year - Only N... - Patient-Friendly (No Needles); No Preserv...No Cold Chain Distribution ...ton,Laboratories, Inc. (OTC Bulletin Board: CARN) ...elSite Biotechnologies, Inc. received a shipment,o...
...stering More Than 180,000 Patient Visits Each Year...ervices Company Aspires to Empower ...OLLS, N.J., Feb. 14 MedeFile,International, Inc. ... in,portable electronic medical records management...ollaborative marketing agreement with Hayes Clinic...
...O, China, Feb. 14 /Xinhua-PRNewswire/ -- Shenzhen ...iotech.com ), the world leader,in the use of umbi...ety of,illnesses, announced that Audrey Jones, the...ay to the United Kingdom (UK) with significant,imp...condition known as,cerebellar atrophy. As the late...
Other Biology Technology:Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 2Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 3Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 4Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 2Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 3Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 4Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility 2Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility 3
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 1Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 2Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 3Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 4Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 5Disparities in cancer care reflect hospital resources U M study finds 54956 1Disparities in cancer care reflect hospital resources U M study finds 54956 2Type 1 diabetes linked to immune response to wheat 54951 1Type 1 diabetes linked to immune response to wheat 54951 2
...PHILADELPHIA (March 17, 2008) -- According to rese... like humans in their responses to many sweet tast...erse range of molecules that humans experience as ...ies. For example, aspartame, a sweetener used by h...However, fruit flies respond positively to most sw...
... Stanford, CACurators at one of the worlds most wi...formation Resource, or TAIR, have joined forces wi...d of information dilemma. It is a first-of-its-kin...r entering important genetics and other biological...em will unclog the information highway and signifi...
...Biotechnology discoveries like the method for cre...nduly hindered or taken hostage by private corpora...1st century, an expert from The Australian Nationa... ANU College of Law takes a broad look at the curr...lectual property rights and biological inventions ...
Other Biology News:Like sweets? You're more like a fruit fly than you think... 2Controlling a sea of information 2Biotechnology needs 21st century patent system: Expert 2
LEVAMISOLE SOLUTION from Invitrogen
Rabbit Anti-Human UCP2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Catch and Release® v2.0
Reversible Immunoprecipitation System from Upstate
DTNB from Cayman Chemical
Biology Products: